TargetBeta
F10
coagulation factor X · also fX · Serine proteases
4 programs in company-led studies act on F10, from 4 companies: 1 in phase 3, 3 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (4 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| emicizumabrule | Hoffmann-La Roche | phase 4 | 134 running | F9 | ChEMBL |
| apixabanrule | Bristol-Myers Squibb | phase 4 | 441 running | – | ChEMBL |
| Rivaroxabanrule | Bayer | phase 4 | 770 running | – | ChEMBL |
| Factor Xrule | Kedrion | phase 3 | 10 running | – | ChEMBL |
Also acted on by the same programs
Conditions their studies are in
- Atrial Fibrillation, 2 programs
- Thrombosis, 2 programs
- Venous Thromboembolism, 2 programs
- Venous Thrombosis, 2 programs
- Acute Coronary Syndrome, 1 program
- Blood Coagulation Disorders, 1 program
- Hemophilia A, 1 program
- Pulmonary Embolism, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 19, 2026emicizumab · Hoffmann-La Roche · phase 4 · NCT05181618
- Jul 31, 2028apixaban · Bristol-Myers Squibb · phase 4 · NCT07870889
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.